[Signal Transduction and Targeted Therapy] The authors review the involvement of aryl hydrocarbon receptor in pathologies such as cancer and autoimmune and inflammatory diseases and its potential as a therapeutic target.

[Cell Death & Disease] Using RNA-seq profiling of TNFR2+ and TNFR2-deficient Treg cells, researchers identified that Trip13 is required for promoting TNF-TNFR2 pathway-mediated Treg expansion.

[Cell Death & Disease] Scientists found that nitric oxide synthases (NOS) 1 expression induces IRF7 modification by S-nitrosylation at the C435 site in mice, which functionally promotes tumor growth in mouse models.

[Molecular Cancer] Researchers identified circROR1 as an oncogenic circular RNA that plays a crucial role in tumor progression and metastasis.

[Cell Discovery] By integrating spatial and temporal dimensions, this framework presented here unifies the multidimensional aspects of wound healing, laying a robust foundation for the development of innovative therapeutic strategies.

[Molecular Cancer] The authors highlight the dual role of intratumoral microbia communities in tumor immune evasion and immunotherapy sensitivity, laying an important theoretical foundation for developing novel immunotherapy strategies targeting tumoral microbiota metabolism.

[Nature Biomedical Engineering] Researchers detected increasing granzyme A in gut biopsies and confirm that CD8+ T cells secrete its active form to induce interleukin-8.

[Nature Reviews Immunology] The authors review the activities of RNA-binding proteins in immune cells and discuss how perturbations of their function can result in immunodeficiency, autoimmunity and chronic inflammation.

[Haematologica] Researchers investigated the RNA-binding protein Quaking, identifying it as a key regulator of splicing with tumor-suppressive properties in T-ALL.

[Medical University of South Carolina] With $1 million in funding from Breakthrough T1D, Dr. Leonardo Ferreira and his collaborators will explore a new approach to treating type 1 diabetes. Dr. Ferreira brings to the field his expertise in engineering the immune system by creating chimeric antigen receptors, that help Tregs to find their targets.

[Coya Therapeutics, Inc. ] Coya Therapeutics, Inc. announced positive results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in nine patients with Frontotemporal Dementia. Data demonstrated enhanced Treg numbers and function and cognitive function stability.

[Cellular & Molecular Immunology] Scientists discovered that the infusion of MSCs restored defects in the splenic stromal cell network and lymphocyte architecture in aged mice while also increasing specific antibody levels following vaccine immunization.